---
title: Air Barrier System Device to Reduce Contamination in Posterior Spine Surgery
nct_id: NCT01559506
overall_status: COMPLETED
phase: NA
sponsor: Nimbic Systems, LLC
study_type: INTERVENTIONAL
primary_condition: Surgery
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT01559506.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT01559506"
ct_last_update_post_date: 2015-03-17
last_seen_at: "2026-05-12T06:40:39.085Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Air Barrier System Device to Reduce Contamination in Posterior Spine Surgery

**Official Title:** ABS to Reduce Contamination in Spine Surgery

**NCT ID:** [NCT01559506](https://clinicaltrials.gov/study/NCT01559506)

## Key Facts

- **Status:** COMPLETED
- **Phase:** NA
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 41
- **Lead Sponsor:** Nimbic Systems, LLC
- **Conditions:** Surgery
- **Start Date:** 2011-11
- **Completion Date:** 2015-02
- **CT.gov Last Update:** 2015-03-17

## Brief Summary

The objective of this study is to determine whether the Air Barrier System (ABS) reduces airborne colony-forming units (e.g. bacteria) present at surgery sites during posterior spinal procedures

## Detailed Description

The ABS is a device that uses localized clean air flow to shield a surgery site from ambient airborne contamination. This study examines the hypothesis that the ABS can reduce the presence of airborne colony-forming units at the surgery site during posterior spinal procedures.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* Adult patients undergoing lumbar and cervical laminectomy with instrumentation.

Exclusion Criteria:

* Active infection
* Prior prosthesis infection
```

## Arms

- **No device** (NO_INTERVENTION) — Subject does not receive ABS system
- **Air Barrier System device** (EXPERIMENTAL) — Device is deployed adjacent to the surgery site and activated.

## Interventions

- **Air Barrier System device** (DEVICE) — Device is deployed adjacent to the surgery site and activated.

## Primary Outcomes

- **CFU Density** _(time frame: Surgical case CFU density will be determined at up to 1 month from completion of surgical cases)_ — Colony-forming unit density at incision site (CFU/m3)

## Locations (1)

- Michael E. DeBakey VA Medical Center, Houston, Texas, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.michael e. debakey va medical center|houston|texas|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT01559506.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT01559506*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*